Shandong Jincheng Pharmaceutical and Chemical Co Ltd
Shandong Jincheng Pharmaceutical Group Co., Ltd researches and develops, produces, markets, and sells Cephalosporin intermediates in China and internationally. It offers medical intermediate, animal nutrition, health care, CMO, CDMO, pharmaceuticals, API, finished dosage, and fine chemicals. Shandong Jincheng Pharmaceutical Group Co., Ltd was founded in 2004 and is based in Zibo, China.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) - Total Assets
Latest total assets as of September 2025: CN¥5.14 Billion CNY
Based on the latest financial reports, Shandong Jincheng Pharmaceutical and Chemical Co Ltd (300233) holds total assets worth CN¥5.14 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Jincheng Pharmaceutical and Chemical Co Ltd's total assets of CN¥5.14 Billion consist of 40.3% current assets and 59.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.4% |
| Accounts Receivable | CN¥703.25 Million | 12.6% |
| Inventory | CN¥598.86 Million | 10.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥754.24 Million | 13.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Shandong Jincheng Pharmaceutical and Chemical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Jincheng Pharmaceutical and Chemical Co Ltd's current assets represent 40.3% of total assets in 2024, a decrease from 58.4% in 2008.
- Cash Position: Cash and equivalents constituted 16.4% of total assets in 2024, down from 21.7% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 10.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 13.5% of total assets.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd Competitors by Total Assets
Key competitors of Shandong Jincheng Pharmaceutical and Chemical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Renxin New Material Co. Ltd. A
SHE:301395
|
China | CN¥1.99 Billion |
|
Engro Corporation Ltd
KAR:ENGRO
|
Pakistan | PKRs765.68 Billion |
|
Fatima Fertilizer Company Ltd
KAR:FATIMA
|
Pakistan | PKRs256.23 Billion |
|
North Huajin Chemical Industries Co Ltd
SHE:000059
|
China | CN¥24.47 Billion |
|
Jiangsu Wujiang China Eastern Silk Market Co Ltd
SHE:000301
|
China | CN¥212.80 Billion |
|
Zangge Holding Co Ltd
SHE:000408
|
China | CN¥16.36 Billion |
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
China | CN¥2.53 Billion |
|
Jilin Gpro Titanium Industry Co Ltd
SHE:000545
|
China | CN¥2.48 Billion |
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shandong Jincheng Pharmaceutical and Chemical Co Ltd generates 0.60x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Shandong Jincheng Pharmaceutical and Chemical Co Ltd generates $ 3.51 in net profit.
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.75 | 1.65 | 1.93 |
| Quick Ratio | 1.26 | 1.20 | 1.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥810.09 Million | CN¥ 871.73 Million | CN¥ 1.07 Billion |
Shandong Jincheng Pharmaceutical and Chemical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Jincheng Pharmaceutical and Chemical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | CN¥5.60 Billion |
| Market Capitalization | $542.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Jincheng Pharmaceutical and Chemical Co Ltd's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shandong Jincheng Pharmaceutical and Chemical Co Ltd's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shandong Jincheng Pharmaceutical and Chemical Co Ltd (2008–2024)
The table below shows the annual total assets of Shandong Jincheng Pharmaceutical and Chemical Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.60 Billion | -5.26% |
| 2023-12-31 | CN¥5.92 Billion | +1.54% |
| 2022-12-31 | CN¥5.83 Billion | +10.44% |
| 2021-12-31 | CN¥5.28 Billion | +5.50% |
| 2020-12-31 | CN¥5.00 Billion | -10.59% |
| 2019-12-31 | CN¥5.59 Billion | +5.78% |
| 2018-12-31 | CN¥5.29 Billion | +7.80% |
| 2017-12-31 | CN¥4.90 Billion | +117.29% |
| 2016-12-31 | CN¥2.26 Billion | +13.05% |
| 2015-12-31 | CN¥2.00 Billion | +11.82% |
| 2014-12-31 | CN¥1.79 Billion | +13.29% |
| 2013-12-31 | CN¥1.58 Billion | +7.21% |
| 2012-12-31 | CN¥1.47 Billion | +5.12% |
| 2011-12-31 | CN¥1.40 Billion | +45.96% |
| 2010-12-31 | CN¥957.95 Million | +38.32% |
| 2009-12-31 | CN¥692.56 Million | +10.61% |
| 2008-12-31 | CN¥626.16 Million | -- |